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The RNA polymerase II-associated protein 1
(RPAP1) is conserved across metazoa and required
for stem cell differentiation in plants; however, very
little is known about its mechanism of action or its
role in mammalian cells. Here, we report that
RPAP1 is essential for the expression of cell identity
genes and for cell viability. Depletion of RPAP1 trig-
gers cell de-differentiation, facilitates reprogram-
ming toward pluripotency, and impairs differentia-
tion. Mechanistically, we show that RPAP1 is
essential for the interaction between RNA polymer-
ase II (RNA Pol II) and Mediator, as well as for the
recruitment of important regulators, such as the
Mediator-specific RNA Pol II factor Gdown1 and
the C-terminal domain (CTD) phosphatase RPAP2.
In agreement, depletion of RPAP1 diminishes the
loading of total and Ser5-phosphorylated RNA
Pol II on many genes, with super-enhancer-driven
genes among the most significantly downregulated.
We conclude that Mediator/RPAP1/RNA Pol II is
an ancient module, conserved from plants to mam-
mals, critical for establishing and maintaining cell
identity.396 Cell Reports 22, 396–410, January 9, 2018 ª 2017 The Author(s)
This is an open access article under the CC BY-NC-ND license (http://INTRODUCTION
Coordinated regulation of RNA polymerase II (RNA Pol II) tran-
scription is central to cell identity transitions and reflects a com-
mon developmental principle across the plant-animal divide
(Gaillochet and Lohmann, 2015; Levine, 2011; Meyerowitz,
2002). High-throughput studies have recently revealed a set of
conserved Pol-II-associated proteins (RPAP1, 2, 3, and 4)
sharing multiple interactions among themselves (Jeronimo
et al., 2004, 2007). RPAP2 is an atypical phosphatase that tar-
gets Ser5P on the RNA Pol II C-terminal domain (CTD) (Egloff
et al., 2012a; Mosley et al., 2009), and RPAP2, RPAP3, and
RPAP4 all have essential roles as nuclear transport chaperones
for the RNA Pol II complex (Boulon et al., 2010; Forget et al.,
2010, 2013). In contrast, the function of RPAP1 remains unchar-
acterized in mammals.
RPAP1 is a large (153-kDa)multidomain protein with a high de-
gree of conservation across species (Jeronimo et al., 2004, 2007;
Sanmartı´n et al., 2011). Studies in plants, yeasts, and mammals
indicate that RPAP1 interacts with the RPB3 (official name
POLR2C) and RPB11 (POLR2J) subunits of the RNA Pol II com-
plex (Giaever et al., 2002; Ito et al., 2001; Jeronimo et al., 2004,
2007; Sanmartı´n et al., 2011). Importantly, the heterodimer
RPB3/RPB11 provides a critical interface of RNA Pol II with the
Mediator complex (Allen and Taatjes, 2015; Davis et al., 2002).
Indeed, a high-throughput screen in yeast indicated that deple-
tion of RPAP1 results in dramatic gene expression changes.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. RPAP1 Expression, Localization, and Requirement for Cell Viability
(A and B) Western blot of RPAP1 expression in a range of pluripotent cell types versus adult tissues (A) or MEFs (B).
(C) Western blot of RPAP1 expression and the ESC marker NANOG during a time course of ESC differentiation by LIF removal and retinoic acid addition.
(D) Immunohistochemical and immunofluorescence staining for RPAP1 in mouse E3.0 morula (upper panel) or E4.0 blastocyst (lower panel). The scale bars
represent 20 mm.
(legend continued on next page)
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that were similar to depletion of the RNA Pol II subunit RPB11,
although these changes were not characterized further (Jero-
nimo et al., 2004, 2007).
The multiprotein Mediator complex associates with transcrip-
tional enhancers through protein-protein interactions, being
critical for enhancer-promoter looping (Allen and Taatjes, 2015;
Jeronimo and Robert, 2017). The largest accumulations of Medi-
ator are in super-enhancers, and super-enhancer target genes
are typically the most important for defining cell identity and
the most heavily dependent on Mediator to drive their transcrip-
tion by RNA Pol II (Allen and Taatjes, 2015; Hnisz et al., 2013;
Kagey et al., 2010; Whyte et al., 2013).
RPAP1 was recently identified in plants as a critical factor for
differentiation by promoting developmental gene expression
(Mun˜oz et al., 2017; Sanmartı´n et al., 2011). Specifically, in Ara-
bidopsis, RPAP1 was necessary and rate limiting to initiate stem
cell differentiation (Sanmartı´n et al., 2011, 2012). Based on this,
we hypothesized that mammalian RPAP1 may also coordinate
gene expression and cell identity at a global level. Here, we char-
acterize the mammalian homolog of RPAP1 to investigate puta-
tive roles in mammalian transcription and differentiation and
reveal a mechanism involving direct RNA Pol II regulation
through interaction with Mediator.
RESULTS
Mammalian RPAP1 Expression
The plant homolog of RPAP1 is highly expressed in stem cells
compared to differentiated cells (Sanmartı´n et al., 2011).
Based on this, we began by examining RPAP1 expression in
pluripotent and differentiated mouse cells. Compared to adult
tissues or mouse embryonic fibroblasts (MEFs), RPAP1 protein
levels were high in embryonic stem cells (ESCs), induced
pluripotent stem cells (iPSCs), embryo carcinoma (P19EC)
cells, and embryoid bodies (EBs) (Figures 1A and 1B). More-
over, RPAP1 expression levels decreased during in vitro differ-
entiation of ESCs by leukemia inhibitory factor (LIF) removal
and retinoic acid addition (Figures 1C and S1A). In the case
of plants, RPAP1 in stem cells is cytoplasmic and only enters
into the nucleus upon differentiation, suggesting that RPAP1
functions as a differentiation switch (Sanmartı´n et al., 2011).
Interestingly, we observed a similar behavior in mouse cells.
In particular, RPAP1 was mostly cytoplasmic in the morula
and blastocyst (Figure 1D), as well as in ESCs undergoing(E–G) Immunofluorescence for RPAP1.
(E) ESCs undergoing self-renewal versus 24 hr differentiation by LIF removal.
(F) ESCs exposed to leptomycin B for 3 hr.
(G) MEFs at day 3 after lentiviral transduction with non-targeting control (shSCR
(H) Immunohistochemical staining for RPAP1 in mouse adult testis. The scale ba
(I) Left panels show ChIP-qPCR for RNA Pol II or RPAP1 enrichment at promoter
renewal conditions or after 24 hr of differentiation by LIF withdrawal and addit
Procedures for ChIP-qPCR primers. Panels on the right show the enhancer hist
2010), where the enhancer is present in ESCs undergoing self-renewal and beco
(J) Quantification of apoptosis by annexin V/propidium iodide co-staining and fluo
lentiviral transduction with non-targeting control (shSCR) or with RPAP1 targetin
(K) Proliferation curves (shown by cumulative population doubling) treated by cont
SD; n = 3 biological replicates.
See also Figure S1.
398 Cell Reports 22, 396–410, January 9, 2018self-renewal (Figures 1E and 1F). However, RPAP1 became
partly nuclear upon ESC differentiation (Figure 1E) and
completely nuclear in differentiated cells and tissues (Figures
1G, 1H, and S1B). Indeed, around gene promoters that
become activated soon after launching differentiation, we
could detect enrichment of RPAP1 coincident with an increase
in H3K27Ac (Figure 1I). Moreover, treatment of ESCs with the
nuclear export inhibitor leptomycin B produced rapid nuclear
accumulation of RPAP1 (Figure 1F), which, similar to plants,
is consistent with active nuclear export of RPAP1 during
stem cell self-renewal. Therefore, mammalian RPAP1 shares
similar expression and subcellular localization dynamics as
observed in plants during the switch between self-renewal
and differentiation.
RPAP1 Is Essential for Cell Viability
To assess the relevance of RPAP1 in cells, we first identified
short hairpin RNAs (shRNAs) that efficiently downregulated
RPAP1 both in mouse and human cells (Figures 1G and S1C;
see also below Figures 4 and S4). RPAP1 knockdown in non-
pluripotent cells, such as human 293T, monkey COS7, various
human cancer cell lines, murineMEFs, and immortalized primary
hepatocytes, severely attenuated proliferation, induced senes-
cence, and triggered apoptosis, typically with a delay of
2–6 days (Figures 1J, 1K, and S1D–S1G). These observations
were recapitulated using a total of three different shRNAs against
murine Rpap1 mRNA (Figure S1F). In contrast to the above cell
types, knockdown of RPAP1 expression had no effect on ESC
viability during self-renewal (Figures 1J, 1K, S1C, S1D, and
S1H). Considering the high levels of RPAP1 in ESCs, we
wondered if shRNA-mediated depletion was not sufficient to
reveal an essential role of RPAP1 on ESC viability. Indeed, we
were unable to obtain viable ESC clones with complete Rpap1
elimination using CRISPR technology. It is important to note
that we successfully targeted the mouse and human RPAP1-en-
coding gene using multiple independent CRISPR delivery sys-
tems (transient, constitutive, or inducible), guide RNAs, and
several wild-type mouse ESC lines or a haploid human cancer
cell line (HAP1). In particular, we obtained many ESC clones
where RPAP1 suffered small deletions but never a complete
loss. Also, when using an ESC line with a LacZ reporter knocked
in within intron 8 of the Rpap1 gene, we were able to efficiently
eliminate LacZ expression using guide RNAs against the first 7
exons of Rpap1; however, we never obtained clones with) or with RPAP1 targeting (shRPAP1) shRNAs.
r represents 30 mm.
s of the indicated genes. Analysis was performed on ESCs maintained in self-
ion of retinoic acid (diff). See resources table in Supplemental Experimental
one mark H3K27Ac enrichment surrounding each promoter (Creyghton et al.,
mes activated after differentiation. Mean ± SD; n = 3 technical replicates.
rescence-activated cell sorting (FACS) of the indicated cell lines at day 6 after
g (shRPAP1) shRNAs. Mean ± SEM; n = 3 replicates; *p < 0.05; **p < 0.01.
rol (shSCR) or lentiviral shRNA against RPAP1 in the indicated cell lines. Mean ±
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elimination of the remaining wild-type Rpap1 allele (Figures S1I–
S1L; see Experimental Procedures). Taken together, the data
suggest that RPAP1 performs an essential function in all the
cell types tested, including ESCs.
RPAP1 Depletion Impairs ESC Differentiation
Whereas strong shRNA depletion of RPAP1 did not affect plurip-
otent cells under self-renewal conditions (see above), we
wondered if we could affect the activation of differentiation pro-
grams. For this, we first assessed differentiation by LIF removal
for 24 or 72 hr (Savatier et al., 1996). We observed that RPAP1-
depleted ESCs presented a delayed differentiation based on the
expression of pluripotency markers andmorphological changes,
followed by an increase in apoptosis (Figures S2A and S2B). Dif-
ferentiation of ESCs to EBs by hanging-drop culture constitutes
a longer term and more complex in vitro differentiation assay.
RPAP1 depletion in ESCs followed by EB differentiation resulted
in severely reduced efficiency of cardiac center development
(formation of beating cell clusters) in EBs (Figure 2A). In agree-
ment, analyses of RNA expression also revealed a delay in the
loss of pluripotency markers and delayed induction of cardiac
muscle differentiation markers associated with RPAP1-depleted
EBs (Figures 2B and S2C), suggesting that a decrease in RPAP1
expression is incompatible with development. Impaired cardiac
center formation by RPAP1-depleted ESCs may reflect their
reduced capacity to differentiate and/or the accumulation of
dying or dysfunctional cells. Consistent with a developmental
defect, Rpap1(+/) ESCs displayed weak contribution to
chimeric offspring (10 from 254 micro-injected embryos; Fig-
ure S2D). Furthermore, when chimeric mice were crossed to
look for germline transmission, we did not obtain mice that were
Rpap1(+/) or Rpap1(/) (0 out of 156 pups born; Figure S2D).
To characterize the influence of RPAP1 on early events during
the pluripotency-to-differentiation transition, we performed RNA
sequencing (RNA-seq) analyses in ESCs, both control andFigure 2. RPAP1 Is Required for the Establishment and Maintenance o
(A) Effect of RPAP1 depletion on embryoid body (EB) cardiac center developm
actively beating cells indicative of cardiac muscle development. The graph
shown.
(B) qPCR analyses of pluripotency or cardiac development markers at the indi
replicates; *p < 0.05.
(C) Overview of RNA-seq transcriptome analyses summarizing differential gene ex
Proportional representation pie chart of significantly differentially expressed genes
genes of high and low expression level remain unchanged.
(D) Ingenuity pathway analysis showing the top 25 most significantly enriched GO
RPAP1 depletion in MEFs (FDR q < 0.01). Terms highlighted in red contain ‘‘de
significance.
(E) Examples of the most significantly up- or downregulated gene sets identified
(FDR q < 0.01). See also Figures S3J and S3K and Table S2.
(F) qPCR validation of RNA-seq data. Mesenchymal, fibroblast, and epithelial mar
day 3 after RPAP1 knockdown in MEFs. Data indicate fold change relative to co
(G) qPCRmeasurement ofmesenchymal and fibroblastmarker mRNA levels durin
with RPAP1 targeting (shRPAP1) shRNAs. Data indicate fold change relative to co
(H) Heatmap summarizing the most significantly up- or downregulated hallmark g
RPAP1 depletion inMEFs (FDR q < 0.01; left column; see Tables S2 and S3) or in E
S1 and S2). Hallmark gene sets with FDR q < 0.25 are significant. Also highlighte
(I) Wound assay scratch test recovery. Graph shows the percent damaged area re
each; *p < 0.05.
See also Figure S2 and Tables S1, S2, and S3.
400 Cell Reports 22, 396–410, January 9, 2018RPAP1 depleted, after 24 hr of differentiation (LIF removal). Of
12,827 transcripts detected, 899 (7.1%) were significantly differ-
entially expressed in RPAP1-depleted cells (Figure S2E; Table
S1). Global investigation via gene set enrichment analysis
(GSEA) and supervised network analyses indicated that,
following RPAP1 depletion, differentiating ESCsmaintained pro-
liferation pathways (Myc and E2F-regulated gene sets were
significantly higher) and had an attenuated induction of mesen-
chymal identity (epithelial-mesenchymal transition [EMT]-related
gene sets were lower) compared to the controls, including key
mesenchymal genes, such as Ctgf, Mest, and Col4a2 (Figures
S2F–S2I; Tables S1 and S2). This is consistent with the delayed
loss of pluripotency markers and morphological changes
observed upon differentiation of RPAP1-depleted ESCs (Figures
2A, 2B, and S2C). Thus, RPAP1 depletion delayed ESC differen-
tiation, suggesting that high levels of RPAP1 endow ESCs with
the ability to rapidly differentiate, whereas reduced levels of
RPAP1 dramatically slow differentiation.
RPAP1 Depletion Induces Loss of Differentiated Cell
Identity
Because RPAP1 depletion impaired ESC differentiation, we
investigated the role of RPAP1 in differentiated cells. Following
RPAP1 depletion in MEFs, cells proliferated and still appeared
morphologically normal during days 1–3, prior to the defects
that subsequently emerged at days 4–6 (see above Figures 1I,
1J, and S1D). Thus, RNA-seq was performed at day 3 in control
or RPAP1-depleted MEFs to assess the transcriptome while
avoiding death-related secondary effects. Nevertheless, tran-
scriptomic alterations were dramatic, with >52% of the 12,249
genes detected displaying significantly altered expression (false
discovery rate [FDR] q < 0.05; Figure 2C; Table S3). Using multi-
ple approaches to assess gene expression, including GSEA,
gene ontology, and supervised network analysis, we observed
that RPAP1 triggered a rapid and pronounced loss of multiplef Cell Identity
ent. EBs were scored daily by microscopy for the appearance of clusters of
shows the kinetics over several days. Representative pictures of EBs are
cated time points from the EB differentiation assay in (A). Mean ± SD; n = 3
pression (FDR q < 0.05) in MEFs at day 3 after RPAP1 depletion. (Upper panel)
is shown. (Lower panel) Dot plot of FPKM values for all genes shows that many
terms among those genes that were significantly downregulated at day 3 after
velopment’’ or ‘‘morphogenesis.’’ Dotted line indicates the basal threshold of
by GSEA analysis in RNA-seq data at day 3 after RPAP1 depletion in MEFs
ker mRNA expression levels were assessed by RNA-seq (left) or qPCR (right) at
ntrol shSCR. Mean ± SD; n = 3 independent MEF lines; *p < 0.05.
g days 1–3 lentiviral transduction ofMEFswith non-targeting control (shSCR) or
ntrol. Mean ± SD; n = 3 independent MEF lines; *p < 0.05. See also Figure S2L.
ene sets identified by GSEA analysis among all gene expression at day 3 after
SCs 24 hr after triggering differentiation (FDR q < 0.05; right column; see Tables
d in the heatmap are borderline gene sets (where FDR q = 0.35–0.25).
maining at +24 hr. Mean ± SD; n = 3 independent MEF lines with 12 replicates
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developmental processes and robust erasure of fibroblast iden-
tity within 3 days (Figures 2F–2H, S2J, and S2K; Tables S2 and
S3), a sequence that was initiated after 24 hr, as confirmed
by qRT-PCR for multiple mesenchymal/fibroblastic identity
markers (Figures 2G and S2L). Notably, there was a remarkable
parallel between the gene sets that were downregulated in MEFs
by RPAP1 loss and the gene sets that failed to be upregulated in
differentiating RPAP1-depleted ESCs (Figure 2H). Moreover,
there was significant overlap in the mRNAs differentially
expressed due to RPAP1 depletion in the two contexts (hyper-
geometric overlap p < 106). Lastly, a defining feature of
mesenchymal cell identity is a high capacity for cell migration.
Consistent with the above gene expression profile, RPAP1
depletion followed by a wound healing scratch assay revealed
an attenuation of MEF migration capacity (Figure 2I). In sum-
mary, after RPAP1 depletion, MEFs display rapid de-differentia-
tion via loss of mesenchymal-fibroblastic identity.
RPAP1 Depletion Favors Reprogramming
Because RPAP1 is important for maintaining the mesenchymal
cell identity of MEFs, we hypothesized that RPAP1 depletion
may recapitulate an early stage of reprogramming to iPSC. Pre-
vious investigators have found that, during reprogramming,
there is an initial de-differentiation wave followed by a transient
intermediate state, which is resolved by a second wave of tran-
scriptional changes, leading to pluripotency (Polo et al., 2012).
Interestingly, the gene expression profile induced by RPAP1
depletion was significantly similar to the intermediate state of re-
programming (Figures 3A, S3A, and S3B). This was supported by
validation with markers of the intermediate state (Polo et al.,
2012), including downregulation ofMeox1 andMeox2 and upre-
gulation of Nup210 (Figure 3B). This suggested that RPAP1
knockdown phenocopies the de-differentiation and loss of
mesenchymal identity observed in the first wave of transcrip-Figure 3. Rpap1 Knockdown Favors De-differentiation and Reprogram
(A) Comparison of gene expression at day 3 after RPAP1 depletion in MEFs versu
showGSEA comparison of the published top 500 genes up- or downregulated at
the current study at day 3 after RPAP1 depletion in MEFs (x axis). See Suppleme
parental MEFs verses Thy1-negative cells at day 3 of iPSC reprogramming. FDR
(B) qPCR measurement of selected genes at day 3 after RPAP1 depletion in M
reported to correlate with cell gene expression during the intermediate stages of i
independent MEF lines; *p < 0.05; **p < 0.01.
(C and D) MEF to iPSC reprogramming after RPAP1 depletion. Expression of the O
of MEFs with non-targeting control (shSCR) or with RPAP1 targeting (shRPAP1)
cycline-induced reprogramming of i4F MEFs that express the four Yamanaka fac
independent i4FMEF lines is shown (mean ±SD; 3 technical replicates). In (C), bot
4F reprogramming is shown. Mean ± SD; n = 3 independent MEF lines; **p < 0.0
formed at day 12 of i4F-MEF doxycycline-induced-OSKM iPSC reprogramming (
FGF2 was added to stimulate reprogramming efficiency.
(E) Summary of outcomes from 32 combinations of OSKMNYamanaka transcriptio
the indicated factors by retroviral delivery, followed by culture in standard iPSC r
proliferation rate, morphology changes, colony formation, staining for alkaline p
cells forming typical iPSC colonies were scored as successfully reprogrammed
positive for alkaline phosphatase and SSEA1 but negative for Sox2-eGFP were s
(F) Examples of alkaline phosphatase staining to indicate formation rates of iPSC
with the indicated combinations of Yamanaka factors ± RPAP1 depletion. Green
programmed iPSC colonies.
(G) qPCR measurement of mesenchymal, epithelial, and pluripotency marker mR
intermediate nature of marker expression displayed by the cells that were gener
See also Figure S3.
402 Cell Reports 22, 396–410, January 9, 2018tional changes during iPSC reprogramming. Consistent with
this, prior knockdown of RPAP1 for 2 days in MEFs led to signif-
icantly enhanced iPSC reprogramming with the four Yamanaka
factors (Oct4, Sox2, Klf4, and Myc, abbreviated as OSKM; Fig-
ures 3C and 3D). Importantly, therefore, the lethality of RPAP1
depletion in MEFs was rescued by reprogramming to pluripotent
iPSCs, suggesting that RPAP1-depleted MEFs at days 2 or 3
may represent de-differentiated cells without a defined identity,
which subsequently collapse unless rescued by reprogramming
into pluripotency.
To explore the minimal complement of the Yamanaka factors
sufficient to rescue lethality of RPAP1 depletion and/or confer
pluripotency, we tested all possible combinations of Oct4,
Sox2, Klf4, Myc, and Nanog (OSKMN) (32 combinations; Fig-
ure 3E), in combination with a panel of media supplements
reported to enhance reprogramming (15 media cocktails; Fig-
ure S3C). Four interesting features emerged: (1) RPAP1 knock-
down plus several of the transcription factor combinations,
including Klf4 or Myc, were sufficient to rescue cell survival; in
particular, shRPAP1 with Klf4/Myc together converted the ma-
jority of MEFs to putative intermediates of reprogramming, that
is, rapidly proliferating colony-forming cells that were also posi-
tive for markers of the early stages of the reprogramming pro-
cess, including alkaline phosphatase and SSEA1 cell surface
expression, but were Sox2-eGFP negative (Figures 3E–3G and
S3D); (2) RPAP1 depletion increased the efficiency of all suc-
cessful reprogramming combinations (Figure 3E); (3) RPAP1
depletion can replace Sox2 in combination with OKM or
OKMN (Figures 3E–3G); and (4) pharmacological inhibition of
transforming growth factor b (TGFb) signaling, which is known
to replace Sox2 (Li et al., 2010), cooperated with RPAP1 deple-
tion in the OKM or OKMN reprogramming (Figure S3E). Taken
together, phenotypic and expression data suggest that RPAP1
depletion induces a de-differentiated state that can be stabilizedming
s a published iPSC roadmap gene expression profile (Polo et al., 2012). Panels
day 3 of the iPSC roadmap versus a ranked list of the gene expression profile in
ntal Experimental Procedures for assessment of the iPSC roadmap data from
q < 0.25 is significant. See also Figures S3A and S3B.
EFs. Downregulation of Meox1 and Meox2 and upregulation of Nup210 were
PSC reprogramming (Hansson et al., 2012; Polo et al., 2012). Mean ± SD; n = 3
SKM reprogramming factors was initiated at day 2 after lentiviral transduction
shRNAs. In (C), top panel, kinetics of iPSC colony appearance during doxy-
tors is shown (see Experimental Procedures). A profile representative of three
tom panel, quantification of iPSC colony yield at day 14 of doxycycline-induced
1. In (D), examples of alkaline phosphatase staining to indicate iPSC colonies
top panel) or retroviral delivery of the OSKM factors (bottom panel) are shown.
n factors. Sox2-eGFPMEFs at day 2 after control or RPAP1 depletion received
eprogramming media. Progress of iPSC reprogramming was assessed by cell
hosphatase, SSEA1 expression, and Sox2-eGFP levels. Sox2-eGFP-positive
iPSCs. Rapidly proliferating cells that initiated colony formation and that were
cored as putative intermediate stages of reprogramming.
colonies and putative intermediate cell types at day 14 of MEF reprogramming
dot indicates those combinations that produced Sox2-eGFP-positive full re-
NA expression levels. Data were converted to heatmap format to highlight the
ated by shRPAP1+Klf4/Myc.
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by Klf4/Myc and can be converted into full pluripotency ifOct4 is
included.
RPAP1 Regulates the RNA Pol II Interactome
To understand the mechanism by which RPAP1 is required for
somatic cell proliferation, we first wondered whether RPAP1
could affect the stability and localization of RNA Pol II. The
RNA Pol II complex is formed by 12 subunits (RPB1–12), where
RPB1 (official name POL2R2A) is the largest and catalytic sub-
unit, and 4 additional associated proteins (RPAP1–4; Wild and
Cramer, 2012). The full complex is assembled in the cytoplasm,
and remarkably, individual depletion of the subunits RPB2–12 or
RPAP2–4 prevents nuclear import of the catalytic subunit RPB1
(Boulon et al., 2010; Forget et al., 2010, 2013; Wild and Cramer,
2012), whereas the effect of RPAP1 depletion has not been re-
ported. Therefore, we assessed the effect of RPAP1 knockdown
on RNA Pol II expression and localization in five different cell
lines. RPAP1 depletion did not affect RNAPol II expression levels
(using as surrogate the catalytic subunit RPB1), or the phosphor-
ylation levels on serine 5 (Ser5P) or serine 2 (Ser2P) of RPB1 (Fig-
ures 4A, S4A, and S4B). In contrast to all the other subunits of the
RNA Pol II complex, depletion of RPAP1 did not affect RNA Pol II
(RPB1) nuclear localization (Figures 4B and S4C). This was
confirmed by immunofluorescence (Figures 4C and S4D). These
observations rule out RNA Pol II destabilization and/or mislocal-
ization as an explanation for the essential role of RPAP1 in the
survival of differentiated cells.
We further investigated the mechanism by which RPAP1
might regulate RNA Pol II. Because RPAP1 is a large protein
directly associated with RNA Pol II (see Introduction), we
compared the RNA Pol II protein interactome of control versus
Rpap1 knockdown MEFs. Immunoprecipitation of the largest
and core RNAPol II subunit (RPB1), followed bymass spectrom-
etry revealed 294 specific interactor proteins (Figure 4D; see
Experimental Procedures), with a clear enrichment for transcrip-
tion-related factors, including, for example, all 12 subunits of the
RNA Pol II complex and almost all (28 out of 30) of Mediator sub-
units, illustrating the depth and specificity of this interactome
analysis (Table S4). Importantly, Rpap1 knockdown did not
affect the integrity of the RNA Pol II complex itself but it resulted
in a significant reduction of 104 RNA Pol II interactors (red circlesFigure 4. RPAP1 Regulates the RNA Pol II Interactome
(A) Western blots of RNA Pol II total (RPB1), Ser5P, or Ser2P expression in whole
b-ACTIN, and LAMIN A/C were used as internal controls.
(B) Western blots of RNA Pol II total (RPB1), Ser5P, or Ser2P expression in nuclear
GAPDH and LAMIN A/C were used as indicators of fraction separation. C, cytop
(C) Immunofluorescence of RNAPol II total (RPB1), Ser5P, or Ser2P inMEFs at day
targeting (shRPAP1) shRNAs. Nuclei were stained with DAPI.
(D) Schematic of the 294 specific interactors of POLR2A/RPB1 detected in primar
analysis (see also Table S4). Interactors were displayed as a network using Cyto
primary function, wherein the thickness and intensity of the connecting edges indic
RPAP1 depletion, the RNA Pol II interactors reduced (circled in red) and RNA Po
depicted centrally and in full color based on the data in Figure 4E, below.
(E) RNA Pol II interactors that were decreased following RPAP1 depletion were
Supplemental Experimental Procedures). On left, complexes are ranked accord
upon RPAP1 depletion from the cells. On right, the total number of subunits per co
and the number of subunits decreased following RPAP1 depletion.
See also Figure S4 and Table S4.
404 Cell Reports 22, 396–410, January 9, 2018in Figure 4D; see also Table S4), whereas 5 new interactors were
found (green circles). Among the RNA Pol II interactors signifi-
cantly affected by RPAP1 depletion, the Mediator complex
was ranked the highest in terms of proportion of affected sub-
units (Figure 4E; Table S4), suggesting an important alteration
in the functions controlled by this complex. Furthermore, we
observed that depletion of RPAP1 led to the loss of Gdown1
(official name POLR2M) from RNA Pol II complexes. Gdown1
is a recently discovered protein that tightly binds approximately
half of RNA Pol II in cells, forming the so-called RNA Pol II(G)
complex (Hu et al., 2006; Jishage et al., 2012). Importantly,
RNA Pol II(G) complexes are known to contain RPAP1 (Jishage
et al., 2012). Finally, it is relevant to note that Gdown1 is re-
cruited by Mediator and associates with RNA Pol II on Medi-
ator-regulated target genes (Cheng et al., 2012; Hu et al.,
2006; Jishage et al., 2012; Li and Price, 2012). Altogether, we
conclude that RPAP1 is a critical ingredient for Mediator-
competent RNA Pol II.
RPAP1 Is Required for Transcription of Identity and
Developmental Genes
Because Mediator has a critical role recruiting RNA Pol II to
genes controlling cell identity and development (Allen and
Taatjes, 2015; D’Alessio et al., 2009; Hnisz et al., 2013; Whyte
et al., 2013), we next investigated the global effect of RPAP1
depletion on RNA Pol II binding to chromatin. For this, we per-
formed chromatin immunoprecipitation sequencing (ChIP-seq)
for total RNA Pol II and for Ser5P RNA Pol II, the latter reflecting
active RNA Pol II (Egloff et al., 2012b; Hsin and Manley, 2012).
Knockdown of RPAP1 in MEFs reduced the abundance of
both total and Ser5P RNA Pol II at about 50% of detected genes,
whereas very few genes (<0.5%) displayed an increase (Figures
5A–5D; Table S5). Interestingly, GSEA and leading edge ana-
lyses revealed that mesenchymal regulators and related devel-
opmental processes were among the gene sets (GSEA) and
genes (leading edge) with the most significant loss of RNA
Pol II (Figures 5E, 5F, and S5A; Table S2).
RNA Pol II regulation at individual genes is oftenmore complex
than overall abundance, particularly in relation to two critical
steps, namely RNA Pol II loading at promoters and transitioning
into productive elongation (Chen et al., 2015; Liu et al., 2015;-cell lysates from a range of cell lines at day 3 after RPAP1 depletion. GAPDH,
/cytoplasmic fractions from a range of cell lines at day 3 after RPAP1 depletion.
lasmic fraction; N, nuclear fraction.
3 after lentiviral transductionwith non-targeting control (shSCR) or with RPAP1
yMEFs in this study by RNA Pol II immunoprecipitation andmass spectrometry
scape and grouped manually by their known physical interactions and general
ate the strength of their known interactions in the STRING database. Following
l II interactors gained (circled in green) are indicated. The Mediator complex is
assigned to all 3,000 known protein complexes in the Corum database (see
ing to the highest percentage of proteins whose interactions were decreased
mplex is indicated, together with the number of subunits detected in this study
A B C
D F G
H
E I
J K
(legend on next page)
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Rahl et al., 2010). Hence, we compared RNA Pol II abundance at
promoter versus gene body by calculating the promoter-to-body
ratio (also referred to as the ‘‘pausing index’’) as described (Chen
et al., 2015; Rahl et al., 2010; Figure S5B). Overall, in those genes
with reliable RNA Pol II signal, we observed that 84% of the
genes in MEFs had a promoter/body ratio >2.0 (Figures S5C
and S5D; Table S5), which is similar to published data in mouse
ESCs (91%; Rahl et al., 2010) or human cancer cells (90%; Chen
et al., 2015). Following RPAP1 depletion, the promoter/body
ratio was altered in many genes; in some cases, it was increased
and in others it was decreased (Figure S5E). Interestingly,
whereas no significant gene sets were enriched among those
genes with decreased promoter/body ratios, gene sets corre-
sponding to regulators of cell identity and development were
significantly present among the genes with increased ratios (Fig-
ure S5E; Table S5).
To investigate whether RPAP1 depletion altered RNA Pol II ac-
tivity and abundance through altered Ser5P levels, we calculated
the Ser5P/total RNA Pol II ratio (also known as ‘‘Ser5P density’’)
for all genes at the promoters and gene bodies. We detected
widespread changes in Ser5P density (Figure S5F), a phenome-
non that has been observed before when RNA Pol II elongation is
blocked (Allepuz-Fuster et al., 2014). Notably, these changes
were more pronounced at promoter regions than at gene bodies
(Figure S5F). Moreover, GSEA analyses revealed that, upon
RPAP1 depletion, the only significantly enriched gene setsFigure 5. RPAP1 Is Required for RNA Pol II Transcription in MEFs, Par
(A and B) ChIP-seq enrichment data after lentiviral transduction of MEFswith non-
plotted as heatmaps of RNA Pol II total (A) or RNA Pol II Ser5P (B) occupancy
decreasing RNA Pol II occupancy at the promoter (100 to +300 bp) in the shSCR
(rpm) (see Supplemental Experimental Procedures—ChIP-seq analysis).
(C) Proportional representation of ChIP data, classifying genes according to the c
the promoter (100 to +300 bp) following RPAP1 depletion in MEFs for 3 days.
(D) Schematics of RNA Pol II total and Ser5P abundance on selected genes, sho
effects (Asap3 and Tulp3).
(E) Table summarizing the most significantly up- or downregulated GO term gene
following RPAP1 depletion in MEFs (see also Tables S2 and S5). Gene sets with
(F) Summary heatmap displaying the overlay of significant GSEA hallmark gene se
on the ranked list of differential mRNA expression in MEFs at day 3 ± RPAP1
expression in ESCs at +24 hr after inducing differentiation ± RPAP1 depletion is sh
all promoters in MEFs at day 3 ± RPAP1 depletion is shown. Column 4: GSEA
tissues ± RPAP1 mutation is shown (Sanmartı´n et al., 2011), following conversion
Supplemental Experimental Procedures, conversion of plant to mouse homologs
(G) GSEA to assess mRNA expression levels of MEF super-enhancer target g
Experimental Procedures) within the transcriptome of primary MEFs at day 3 a
ure S5G.
(H) Plots show the average eRNA levels within two groups of MEF super-enha
decreased (n = 64 enhancers; bottom panel) in MEFs at day 3 after RPAP1 knoc
(I) GREAT analysis was used to identify target genes for each of the two super-e
These two sets of target genes (with increased eRNAs or with decreased eRN
developmental Theiler stages (these gene groups are detailed in Figures S5H and
genes of interest is represented (gray dots) together with the average (red) and S
(J and K) Model for RPAP1 function in the mechanism for triggering developmen
(J) In self-renewing ESCs, RPAP1 (in green) is abundantly expressed and pred
permits increased transcriptional regulation and activation of developmental progr
enhanced susceptibility for reprogramming toward pluripotency.
(K) Taken together, our data suggest a model where RPAP1 exists in a complex w
axis. Thus, loss of RPAP1 triggers a decrease in the association between Medi
phosphatase RPAP2), preferentially affecting the ability of enhancers to activateM
cell identity. In somatic cells, such as MEFs, this leads to de-differentiation, as ex
See also Figure S5 and Table S5.
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and these included gene sets and gene ontology (GO) terms,
such as TNFa signaling via NFkB, cell migration, locomotory
behavior, and genes in which RNA levels are also downregulated
(Tables S2 and S5), such as Snai2, Tgfb1i1, Tgfb3, Tgfbrap, Lox,
Loxl1, Tlr2, Tlr3, Vegfa, Myo6, Smad6, Ccl7, S100a4 (fibroblast-
specific protein1), and S100a6 (Figure S5F; Table S5). Taken
together, this suggests that RPAP1 depletion affects RNA
Pol II transcription, including the levels of Ser5P, and this prefer-
entially perturbs the expression of cell identity and develop-
mental regulators.
In summary, upon Rpap1 knockdown in MEFs, the genes and
gene sets linked to the regulation of fibroblastic/mesenchymal
identity or closely related developmental processes were the
most significantly enriched in four key categories: (1) genes
with the most significantly downregulated mRNA expression;
(2) genes with the greatest overall depletion of RNA Pol II;
(3) genes with selective RNA Pol II depletion from their gene
body; and (4) genes with the most enhanced Ser5P density at
their promoters.
Conservation of RPAP1 Function from Plants to
Mammals
Previously, it was shown thatmutations of the RPAP1 homolog in
plants inhibited cell differentiation, and microarray analyses
showed a specific defect on developmental gene expressionticularly on Developmental and Mesenchymal Genes
targeting control (shSCR) or with RPAP1 targeting (shRPAP1) shRNAs. Data are
around the transcriptional start site (TSS) region ± 5 Kb. Rows are sorted by
control. Color-scaled intensities are in units of reads per million mapped reads
hanges in abundance of RNA Pol II total (upper panel) or Ser5P (lower panel) at
wing examples of RNA Pol II depletion (S100a4, Snai1, and Snai2) or minimal
sets identified by GSEA among the genes with >23-fold decrease in RNA Pol II
FDR q value < 0.25 were considered significant.
ts across 4 experiments (columns 1 and 2: see also Figure 2H). Column 1: GSEA
depletion is shown. Column 2: GSEA on the ranked list of differential mRNA
own. Column 3: GSEA on the ranked list of differential RNA Pol II abundance at
on the ranked list of differential gene expression in Arabidopsis thaliana plant
to the nearest mouse homolog based on protein sequence conservation (see
, and Table S2).
enes (n = 661; defined by GREAT analysis as described; see Supplemental
fter Rpap1 knockdown. Compare with housekeeper gene expression in Fig-
ncers regions: those which were increased (n = 63 enhancers; top panel) or
kdown.
nhancer groups identified in (H) (see Supplemental Experimental Procedures).
As, respectively) were compared with gene groups associated to particular
S5I). The Theiler stage of those gene groups with high similarity to our target
EM (black).
t.
ominantly cytoplasmic. Upon differentiation, nuclear accumulation of RPAP1
ams. Depletion of RPAP1 in differentiated cells results in loss of cell identity and
ith RNA Pol II and plays an essential role in the Mediator-RNA Pol II regulatory
ator and RNA Pol II (including the key regulators Gdown1 [G] and the Ser5P
ediator target genes, which are known to include keymarkers and regulators of
pression of fibroblastic, mesenchymal, and developmental markers is erased.
(Sanmartı´n et al., 2011). In order to directly compare the mouse
and plant functional overlap, we converted the published plant
differential gene expression data to the nearest mammalian pro-
tein homolog where possible (see Experimental Procedures and
Table S2). Interestingly, conversion of the plant expression data
to mouse homologs also revealed significant downregulation of
developmental processes (Figure 5F; Table S2). This suggests
that loss of RPAP1 function in mice and plants downregulates
similar developmental processes, including lineage specifiers
and regulators of cell identity, such as hypoxia, cell polarity,
extra-cellular matrix, and chemokine signaling.
RPAP1 Preferentially Regulates Mediator-Driven Gene
Expression
Mediator physically links enhancers with target genes and then
recruits RNA Pol II for their transcriptional activation (Allen and
Taatjes, 2015). This process is especially critical tomaintain tran-
scription of genes regulated by super-enhancers, which typically
encode key markers and regulators of cell identity (Allen and
Taatjes, 2015; Hnisz et al., 2013; Whyte et al., 2013). Given our
observations above that RPAP1 depletion triggered both a
decrease in RNA Pol II interaction with the Mediator complex
and selective loss of cell identity gene expression, we next as-
sessed the transcription of super-enhancer-driven genes. We
found that following RPAP1 depletion in MEFs, the mRNA
levels of genes proximal to super-enhancers were significantly
decreased (Figure 5G), whereas highly expressed housekeeper
genes were not affected (Figure S5G). Expression levels of
enhancer RNAs (eRNAs) are proportional to their enhancer activ-
ity (Andersson et al., 2014; Li et al., 2016). In our RNA-seq, we
detected eRNA expression in 20% of super-enhancers, and
we divided those enhancers into two groups, those with
increased or decreased eRNA levels (Figure 5H). Interestingly,
after RPAP1 depletion, enhancers with decreased eRNA levels
(decreased activity) had target genes associated with Theiler
stages 20–25 (embryonic day 11.5 [E11.5]–17), whereas en-
hancers with increased eRNA levels (increased activity) had
target genes associated with Theiler stages 14–20 (E8–13; Fig-
ures 5I and S5H). Because MEFs arise from E13.5 embryos,
the data suggest that enhancers of this embryo stage are
decreased in activity, whereas enhancers of earlier embryo
stages are activated. This is consistent with the de-differentia-
tion effects that we observed above in MEFs after RPAP1 deple-
tion. Taken together, this suggests that RPAP1 depletion affects
RNA Pol II transcription by disruption of the Mediator/RNA Pol II
interaction, and this preferentially reduces the expression of
super-enhancer-driven cell identity and developmental regula-
tors (Figures 5J and 5K).
DISCUSSION
We have characterized the function of mammalian RPAP1 and
observed prominent parallels with its plant homolog in terms of
subcellular localization, developmental expression patterns,
regulation of RNA polymerase II transcription, and a requirement
to establish and maintain differentiated cell identity. Based on
this, we propose that this is an ancient mechanism to trigger
the transition from pluripotency to differentiation.RPAP1 Nucleo-cytoplasmic Shuttling
We found that RPAP1 protein is very abundant and largely cyto-
plasmic in pluripotent cells, which is consistent with the apparent
lack of effect of RPAP1 depletion on self-renewing pluripotent
cells. However, we cannot exclude the possibility that Rpap1
knockdown has some impact on self-renewal pathways, and
we note that we were unable to isolate Rpap1 knockout (KO)
ESCs, suggesting that ESCs require a small fraction of RPAP1
either for an essential function or tomaintain fast proliferation un-
der self-renewal conditions. Interestingly, we observed rapid nu-
clear accumulation of RPAP1 by blocking nuclear export,
implying a continuous cycle of RPAP1 in/out of pluripotent cell
nuclei. In contrast, the onset of differentiation coincided with
RPAP1 nuclear accumulation, observed both in vitro and in vivo,
and recruitment to promoters together with RNA Pol II. In fact,
this developmental switch in nucleo-cytoplasmic shuttling is
similar to the behavior of the RPAP1 plant homolog (Mun˜oz
et al., 2017; Sanmartı´n et al., 2011, 2012). This is also consistent
with the existence of multiple conserved nuclear localization
signals (NLS)/nuclear export signal (NES) sequences on
RPAP1 and an armadillo superfamily repeat region (ARM), a
motif associated with nucleo-cytoplasmic shuttling, that is highly
conserved in RPAP1 homologs of Saccharomyces, Drosophila,
and mammals (Jeronimo et al., 2004). Together, this suggests
a conserved model for RPAP1 in the mechanism for triggering
development (Figure 5J).
RPAP1 Is Required to Establish and Maintain Cell
Identity
During development, new cell identity can arise through a series
of reversible epithelial-to-mesenchymal transitions (EMTs)
(Thiery et al., 2009). RPAP1 expression was required during
ESC differentiation, including toward cardiac muscle develop-
ment, a path containing several EMT transitions (Thiery et al.,
2009). Consistent with this, we failed to obtain homozygous
Rpap1-null mice. Moreover, RPAP1 depletion resulted in a strik-
ing loss of the mesenchymal identity of MEFs and subsequent
cell death. Similarly, all tested cell lines (a total of 8) died several
days after RPAP1 depletion or attempted CRISPR knockout.
Taken together, these data suggest a role for RPAP1 in estab-
lishment and maintenance of cell identity and this explains why
its complete elimination is incompatible with cell viability.
RPAP1 Depletion Permits De-differentiation and
Reprogramming
RPAP1 depletion in MEFs induced loss of the mesenchymal/
fibroblastic identity. Strikingly, however, such de-differentiation
complemented the early stages of reprogramming to pluripotent
iPSCs, and thus, RPAP1 depletion enhanced the efficiency of re-
capturing pluripotency. Therefore, reprogramming with OSKM
rescued the lethality of RPAP1 depletion, a phenomenon we
found could be attributed to the overexpression of Klf4 plus
Myc in particular. We hypothesize that Klf4/Myc dual overex-
pression may revert or compensate the lethal effects of RPAP1
depletion because MYC amplifies active RNA Pol II transcription
(Lin et al., 2012; van Riggelen et al., 2010), whereas the
ectodermal lineage specifier KLF4 may help to specify a new
epithelial identity. In this way, RPAP1 depletion plus Klf4/MycCell Reports 22, 396–410, January 9, 2018 407
overexpression may stabilize a highly proliferative reprogram-
ming intermediate.
RPAP1 Acts at the Interface between RNA Pol II and
Mediator
RPAP1 is a large (153-kDa)multidomain protein that has been re-
ported to bind a number of interesting RNA Pol II regulators,
most notably the RPB3/11 heterodimer, and this is well substan-
tiated in plants, yeasts, and mammals (Giaever et al., 2002;
Hazbun et al., 2003; Ito et al., 2001; Jeronimo et al., 2004,
2007; Sanmartı´n et al., 2011). Indeed, loss of RPAP1 in yeast pro-
duces global changes in gene expression that resemble those
produced by loss of RPB11 (Jeronimo et al., 2004). The RPB3/
RPB11 heterodimer provides the interface between RNA Pol II
and theMediator complex (Davis et al., 2002). Importantly, Medi-
ator plays a critical role in establishing cell identity (Allen and
Taatjes, 2015; Hnisz et al., 2013; Jeronimo and Robert, 2017;
Whyte et al., 2013), and RPB3 is reported to specify muscle iden-
tity (Corbi et al., 2002). Here, we detected a major disruption of
the RNA Pol II interactome following RPAP1 depletion, and
most notably, out of 3,000 known protein complexes in the
Corum database, the complex most heavily affected was the
Mediator complex. Therefore, our current findings suggest a
model whereby RPAP1 operates at the interface between RNA
Pol II and Mediator to direct the transcription of cell identity
genes.
RPAP1 Is Required for RNA Pol II Transcription at Cell
Identity Genes
Consistent with the pivotal role of RPAP1 in the Mediator/RNA
Pol II axis, we observed widespread transcriptional changes in
RPAP1-depleted MEFs, with significantly altered gene expres-
sion in 52% of all detectable mRNAs and decreased RNA Pol II
loading in 50%–60% of all genes. However, we also observed
that about 40% of genes displayed minimal changes in RNA
Pol II abundance (Figure 5C), and many highly expressed
mRNAs remained unaffected (Figures 2C and S5G), arguing
against a non-specific defect in RNA Pol II transcription. Further-
more, upon RPAP1 knockdown inMEFs, genes regulating devel-
opmental processes and fibroblastic/mesenchymal identity
were the most significantly affected according to four criteria:
(1) downregulated mRNA expression; (2) greatest overall deple-
tion of RNA Pol II; (3) increased Ser5P RNA Pol II density at pro-
moters; and (4) depletion of RNAPol II within gene bodies relative
to promoters. These features are consistent with RPAP1 deletion
affecting RNA Pol II loading on promoters and promoter escape
into gene bodies. Remarkably, these aspects mirror Mediator’s
best known functions (Jeronimo and Robert, 2017).
Our proteomic data provide mechanistic explanations for the
relative increase in Ser5P RNA Pol II at promoters and for the
relative reduction of RNA Pol II from gene bodies. In particular,
RPAP1 has conserved interactions with the Ser5P phosphatase
RPAP2 in plants and mammals (Egloff et al., 2012a; Jeronimo
et al., 2007; Mosley et al., 2009; Mun˜oz et al., 2017). We
observed that RPAP2 phosphatase was depleted from the
Pol II interactome upon knockdown of RPAP1, and this may
explain the relative accumulation of Ser5P RNA Pol II at
promoters. Meanwhile, Gdown1 (official name POLR2M) is a408 Cell Reports 22, 396–410, January 9, 2018recently discovered protein, often referred to as ‘‘the 13th sub-
unit,’’ that tightly binds approximately half of the RNA Pol II com-
plexes in cells, forming RNA Pol II(G) (Hu et al., 2006; Jishage
et al., 2012). Specifically, Gdown1 is recruited by Mediator and
associates with RNA Pol II on Mediator-regulated target genes
(Cheng et al., 2012; Hu et al., 2006; Jishage et al., 2012; Li and
Price, 2012). It has been reported that RNA Pol II(G) contains
RPAP1 (Jishage et al., 2012), and here, we show that depletion
of RPAP1 leads to the loss of Gdown1 from RNA Pol II com-
plexes. Therefore, RPAP1 acts as a critical ingredient for Medi-
ator-competent RNA Pol II.
Mediator is most abundant in super-enhancers, and super-
enhancer target genes are typically the most important for
defining cell identity and the most heavily dependent on Medi-
ator to drive their transcription by RNA Pol II (Allen and Taatjes,
2015; Hnisz et al., 2013; Jeronimo and Robert, 2017; Whyte
et al., 2013). In agreement, the gene expression of super-
enhancer target genes was preferentially decreased following
RPAP1 depletion in MEFs, and this pattern of gene expression
correlates closely with the first 3 days of iPSC reprogramming,
constituting a de-differentiation effect. Consistent with a de-dif-
ferentiation effect, we observed that the activity of enhancers,
measured by their eRNA levels, shifted from the developmental
stage of MEFs toward an earlier developmental stage. This is
consistent with recent evidence that, during cell identity transi-
tions, coordinated changes in enhancer activity lead the re-orga-
nization of transcriptional networks (Arner et al., 2015; Factor
et al., 2014). Taken together, the data point toward a primary
role for RPAP1 in maintaining the expression of identity regula-
tors through the Mediator/RNA Pol II axis.
Conclusions
Collectively, our data point toward a developmental requirement
for mammalian RPAP1, both in establishing and maintaining cell
identity, through direct regulation of RNA polymerase II tran-
scription. Mechanistically, we present evidence suggesting a
unified model whereby RPAP1 operates by coordinating the
communication between Mediator and RNA Pol II, particularly
on super-enhancer-driven genes.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures.
Animal Experimentation
Experiments with mice at the CNIO,Madrid, were performed according to pro-
tocols approved by the CNIO-ISCIII Ethics Committee for Research and Ani-
mal Welfare (CEIyBA).
Cell Culture, RPAP1 Knockdown, and CRISPR-Cas9 Knockout
Primary MEFs (wild-type; passage 2) were obtained at E13.5 from pure inbred
C57BL6 background mice. Immortalized primary mouse hepatocytes HEP
cells have been previously described (Lopez-Guadamillas et al., 2016). Mouse
P19EC cells, monkey COS7 cells, and the human cell lines 293T, HCT116,
SCC42B, and H226 were from ATCC. All the above-mentioned cells were
maintained in DMEM medium with 10% fetal bovine serum (FBS) (Gibco)
with antibiotics (penicillin/streptomycin 100 U/mL). For ESC culture and
iPSC reprogramming conditions, see the Supplemental Experimental Proced-
ures for full details. For shRNA knockdown or overexpression methods with
retroviral and lentiviral vectors and for a detailed description of the CRISPR-
Cas9 strategies used here, see the Supplemental Experimental Procedures
for full details.
RNA Pol II Protein Interactome and Protein Expression Analysis
RNA Pol II immunoprecipitation, interactome analysis, and liquid chromatog-
raphy (LC)/LC mass spectrometry was performed on day +2 after lentiviral
shRNA knockdown of RPAP1 in primary MEFs. See the Supplemental Exper-
imental Procedures for full details. For analysis of protein expression by
western blot, immunofluorescence, cytometry, and histopathology, see the
Supplemental Experimental Procedures for full details.
RNA Isolation and Gene Expression Analyses by qRT-PCR or RNA-
Seq
Total RNA was extracted from cells on column by RNeasy kit with DNA diges-
tion following provider’s recommendations (QIAGENno. 74104) and retro-tran-
scribed into cDNA followingmanufacturer’s protocol with Superscript Reverse
Transcriptase (Life Technologies). Real-time qPCRwas performed using Syber
Green Power PCR Master Mix (Applied Biosystems) in an ABI PRISM 7700
thermocycler (Applied Biosystems). Primers are listed in the resource table in
Supplemental Experimental Procedures. For RNA-seq transcriptomic ana-
lyses, see the Supplemental Experimental Procedures for full details.
Chromatin Immunoprecipitation: ChIP-qPCR and ChIP-Seq
ChIP-qPCRwas performed with antibodies for total RNA Pol II and RPAP1 and
with primers listed in the resource tables in Supplemental Experimental Pro-
cedures. ChIP-seq for RNA Pol II was performed as described (Rahl et al.,
2010). See the Supplemental Experimental Procedures for full details of
ChIP-seqmethods, analyses, and definition of promoter and enhancer regions
Quantification and Statistical Analysis
Unless otherwise specified, quantitative data are presented as mean ± SD and
significance was assessed by the two-tailed Student’s t test; *p < 0.05;
**p < 0.01; ***p < 0.001.
DATA AND SOFTWARE AVAILABILITY
The accession number for the three datasets (two RNA-seq and one ChIP-seq
experiments) reported in this paper is GEO: GSE78795. The accession number
for the mass spectrometry proteomics data reported in this paper is
ProteomeXchange: PXD007114.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.12.062.
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